A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 341 participants.

Also called NCT02277691

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 341 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02277691
  • WHO UTN U1111-1163-0169
Other papers using this trial's data
  • A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension Blood pressure, 2018-06 DOI, PubMed 29235365 PubMed links an erratum for this paper. Erratum: PMID 29357704

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02277691. Allocation not applicable; no masking; primary purpose treatment. Start 2014-11-07 (actual); primary completion 2016-04-25 (actual). Results posted on 2017-06-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
TAK-536TCH tablet
Intervention (Drug)
TAK-536CCB tablet
Intervention (Drug)
HCTZ 12.5 mg tablet
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02277691
Content hash
2f2af60633503a4a2289b46ba37bca0b6d1397c2172b231a3a114d3d5cfbcf13